News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

Al's Comment:

This is probably the most important article about Optune.  It updates the data reported the prior year and shows a little better results.  If you can maintain over 90% compliance, the  % of patients alive at 5 years was 29.3% compared to 4.5% in the control group which was Temodar and whatever else the doctor and patient wanted to use.  This is the best survival rate ever reported in a large brain tumor trial and should finally put to rest any resistance to it's use.  At this point, Optune (plus Temodar)  should be considered the new standard of care.


Posted on: 01/26/2019

Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740